Patients with malignant brain tumors have poor prognoses even when treated with the best conventional therapy of surgical resection, radiation therapy, and chemotherapy. Hence, investigation of new therapeutic approaches for these neurological diseases is needed. One novel approach has been the introduction of genes into tumor cells that render them sensitive to cytotoxic drugs. Previous experiments demonstrated a robust tumoricidal activity against experimental brain using the herpes simplex virus thymidine kinase (HSVtk) gene that converts ganciclovir (GCV) to a form that is cytotoxic to rapidly dividing cells. The treatment was not as effective when tested with tumors generated from cell lines with lesser immunogenicity. These observations suggest that the tumoricidal activity results from two processes: (1) direct tumoricidal activity of HSV-tk conversion of GCV and (2) cellular immune responses. The applicant will test the hypothesis that cell death from HSV-tk/GCV treatment causes antigen presenting cells (APCS) to activate cytotoxic T lymphocyte (CTL) precursors which then destroy residual tumor and prohibit further cell growth. The presence of an immunological component can explain the weaker tumoricidal activity observed in models in which the hosts were immunoincompetent or in which the cell lines were less immunogenic. If this hypothesis is correct then (1) depending on their immunogenicity, different tumor cell lines will elicit different immune responses to HSV-tk/GCV-mediated cell death in vivo as measured by immunological analyses, and (2) neuroimmune modulation by cytokine gene transfer will elicit a heightened CTL response to the tumor cells. The objective of this project is to delineate the neuroimmunological mechanisms of cell death in experimental brain tumors following initial killing by HSV-tk/GCV treatment.
The Specific Aims are to: (1) characterize the immunological response to HSV-tk/GCV-mediated death of syngeneic experimental tumors generated by 3 glial tumor cell lines with different degrees of immunogenic potential, (2) measure the tumoricidal effects of in situ immune modulation by adenovirus-mediated transduction of tumors with the genes for the cytokines IL-2, GM-CSF, TNFA. and IL-12 with and without HSV-tk/GCV treatment. and (3) characterize the immunological responses elicited by adenoviral-mediated cytokine immune modulation with and without HSV-tk/GCV treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
3R01NS035280-03S1
Application #
6094493
Study Section
Special Emphasis Panel (ZRG1 (01))
Program Officer
Jacobs, Tom P
Project Start
1997-07-15
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2001-06-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Chen, Qin; Smith, George M; Shine, H David (2008) Immune activation is required for NT-3-induced axonal plasticity in chronic spinal cord injury. Exp Neurol 209:497-509
Qi, Hong; Li, De-Quan; Shine, H David et al. (2008) Nerve growth factor and its receptor TrkA serve as potential markers for human corneal epithelial progenitor cells. Exp Eye Res 86:34-40
Qi, Hong; Shine, H David; Li, De-Quan et al. (2008) Glial cell-derived neurotrophic factor gene delivery enhances survival of human corneal epithelium in culture and the overexpression of GDNF in bioengineered constructs. Exp Eye Res 87:580-6
Qi, Hong; Chuang, Eliseu Yung; Yoon, Kyung-Chul et al. (2007) Patterned expression of neurotrophic factors and receptors in human limbal and corneal regions. Mol Vis 13:1934-41
Chen, Qin; Zhou, Lijun; Shine, H David (2006) Expression of neurotrophin-3 promotes axonal plasticity in the acute but not chronic injured spinal cord. J Neurotrauma 23:1254-60
Grider, M H; Mamounas, L A; Le, W et al. (2005) In situ expression of brain-derived neurotrophic factor or neurotrophin-3 promotes sprouting of cortical serotonergic axons following a neurotoxic lesion. J Neurosci Res 82:404-12
Zhou, Lijun; Shine, H David (2003) Neurotrophic factors expressed in both cortex and spinal cord induce axonal plasticity after spinal cord injury. J Neurosci Res 74:221-6
Zhou, Lijun; Baumgartner, Brian J; Hill-Felberg, Sandra J et al. (2003) Neurotrophin-3 expressed in situ induces axonal plasticity in the adult injured spinal cord. J Neurosci 23:1424-31